Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Case Rep
Main Authors: Nagashima, Kana, Kikuchi, Shohei, Iyama, Satoshi, Fujita, Chisa, Goto, Akari, Horiguchi, Hiroto, Kobune, Masayoshi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7069848/
https://ncbi.nlm.nih.gov/pubmed/32185037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2688
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados